Patents by Inventor Jonathan Mark Sutton

Jonathan Mark Sutton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF
    Publication number: 20260132117
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Application
    Filed: October 21, 2025
    Publication date: May 14, 2026
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Duncan Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • Urolithin derivatives and methods of use thereof
    Patent number: 12473269
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: November 18, 2025
    Assignee: Vandria SA
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • Compounds Useful as RET Inhibitors
    Publication number: 20250243202
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
    Type: Application
    Filed: July 31, 2024
    Publication date: July 31, 2025
    Applicant: Cancer Research Technology Limited
    Inventors: Allan Jordan, Rebecca Newton, George Hynd, Jonathan Mark Sutton, Bohdan Waszkowycz
  • Heterocyclic Compounds as RET Kinase Inhibitors
    Publication number: 20250236624
    Abstract: The present invention relates to compounds of Formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
    Type: Application
    Filed: December 3, 2024
    Publication date: July 24, 2025
    Applicant: Cancer Research Technology Limited
    Inventors: Allan Michael Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
  • Urolithin derivatives and methods of use thereof
    Patent number: 12358884
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: July 15, 2025
    Assignee: Vandria SA
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • Urolithin derivatives and methods of use thereof
    Patent number: 12351567
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: July 8, 2025
    Assignee: Vandria SA
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF
    Publication number: 20240158365
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Application
    Filed: November 16, 2023
    Publication date: May 16, 2024
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF
    Publication number: 20240158364
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Application
    Filed: November 16, 2023
    Publication date: May 16, 2024
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhen, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF
    Publication number: 20240158363
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Application
    Filed: November 16, 2023
    Publication date: May 16, 2024
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • Compounds Useful as RET Inhibitors
    Publication number: 20240132504
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
    Type: Application
    Filed: May 4, 2023
    Publication date: April 25, 2024
    Applicant: Cancer Research Technology Limited
    Inventors: Allan Jordan, Rebecca Newton, George Hynd, Jonathan Mark Sutton, Bohdan Waszkowycz
  • Heterocyclic Compounds as RET Kinase Inhibitors
    Publication number: 20240116938
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, X1, X2, X3, X4, integer a and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
    Type: Application
    Filed: April 18, 2023
    Publication date: April 11, 2024
    Applicant: Cancer Research Technology Limited
    Inventors: Allan Michael Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
  • Urolithin derivatives and methods of use thereof
    Patent number: 11820751
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: November 21, 2023
    Assignee: Vandria SA
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen Mary Seward, Jamie D. Knight, Ian Linney, Peter C. Sennhenn, Said Oumouch, Florent Beaufils, Thomas Christian Fessard
  • Heterocyclic Compounds as RET Kinase Inhibitors
    Publication number: 20230339954
    Abstract: The present invention relates to compounds of Formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
    Type: Application
    Filed: November 22, 2022
    Publication date: October 26, 2023
    Applicant: Cancer Research Technology Limited
    Inventors: Allan Michael Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
  • Compounds useful as RET inhibitors
    Patent number: 11680068
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: June 20, 2023
    Assignee: Cancer Research Technology Limited
    Inventors: Allan Jordan, Rebecca Newton, George Hynd, Jonathan Mark Sutton, Bohdan Waszkowycz
  • Heterocyclic compounds as RET kinase inhibitors
    Patent number: 11661423
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, X1, X2, X3, X4, integer a and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: May 30, 2023
    Assignee: Cancer Research Technology Limited
    Inventors: Allan Michael Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
  • Substituted imidazo[1,5-a]pyrazines for IRE1 inhibition
    Patent number: 11649237
    Abstract: Provided herein, inter alia, are substituted imidazo[1,5-?]pyrazine compounds, compositions and methods for treating or preventing an IRE1?-related disease or disorder. In certain embodiments, the disease or disorder is selected from the group consisting of a neurodegenerative disease, a demyelinating disease, cancer, an eye disease, a fibrotic disease, and diabetes.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: May 16, 2023
    Assignees: Optikira LLC, The Regents of the University of California
    Inventors: Richard M. Keenan, Bradley J. Backes, Dustin J. Maly, Charles Reynolds, Ben Whittaker, Jamie Knight, Jonathan Mark Sutton, George Hynd, Feroz R. Papa, Scott A. Oakes
  • Heterocyclic compounds as RET kinase inhibitors
    Patent number: 11548896
    Abstract: The present invention relates to compounds of Formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: January 10, 2023
    Assignee: Cancer Research Technology Limited
    Inventors: Allan Michael Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
  • Compounds Useful as RET Inhibitors
    Publication number: 20220348585
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
    Type: Application
    Filed: May 6, 2022
    Publication date: November 3, 2022
    Applicant: Cancer Research Technology Limited
    Inventors: Allan Jordan, Rebecca Newton, George Hynd, Jonathan Mark Sutton, Bohdan Waszkowycz
  • UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF
    Publication number: 20220259173
    Abstract: Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
    Type: Application
    Filed: January 27, 2022
    Publication date: August 18, 2022
    Inventors: Christopher L. Rinsch, Penelope Andreux, Jonathan Mark Sutton, Eileen M. Seward, Jamie D. Knight, Lan Linney, Peter C. Sennhenn
  • Compounds useful as RET inhibitors
    Patent number: 11352361
    Abstract: The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: June 7, 2022
    Assignee: Cancer Research Technology Limited
    Inventors: Allan Jordan, Rebecca Newton, George Hynd, Jonathan Mark Sutton, Bohdan Waszkowycz